AAM
PCRX icon

Azzad Asset Management’s Pacira BioSciences PCRX Stock Holding History

Azzad Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-9,384
Closed -$274K – 311
2024
Q1 		$274K Buy
9,384
+185
+2% +$5.68K 0.03% 284
2023
Q4 		$310K Buy
+9,199
New +$269K 0.04% 288
2023
Q3 		– Sell
-6,204
Closed -$249K – 318
2023
Q2 		$249K Buy
6,204
+158
+3% +$6.53K 0.03% 308
2023
Q1 		$247K Buy
6,046
+239
+4% +$9.51K 0.04% 303
2022
Q4 		$224K Buy
5,807
+77
+1% +$3.75K 0.04% 300
2022
Q3 		$305K Buy
5,730
+1,798
+46% +$100K 0.03% 372
2022
Q2 		$229K Buy
3,932
+82
+2% +$5.37K 0.02% 382
2022
Q1 		$294K Sell
3,850
-917
-19% -$61.1K 0.04% 307
2021
Q4 		$287K Sell
4,767
-20
-0.4% -$1.1K 0.04% 315
2021
Q3 		$268K Buy
4,787
+115
+2% +$6.63K 0.04% 312
2021
Q2 		$284K Sell
4,672
-62
-1% -$3.92K 0.04% 306
2021
Q1 		$332K Buy
4,734
+94
+2% +$6.71K 0.06% 289
2020
Q4 		$278K Buy
4,640
+164
+4% +$9.6K 0.05% 271
2020
Q3 		$269K Buy
+4,476
New +$260K 0.06% 273

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Azzad Asset Management's PCRX Position: Q2 2024 in Review

Azzad Asset Management sold out of Pacira BioSciences (PCRX) in Q2 2024, closing a stake of 9,384 shares — an estimated $274K sold.

Azzad Asset Management first reported a position in PCRX in Q3 2020 and held it in 14 quarters. The position peaked at $332K in Q1 2021. 280 funds tracked by Wall St. Rank hold PCRX as of Q2 2024.

  • Azzad Asset Management reported no remaining Pacira BioSciences position as of Q2 2024 after selling out during the quarter.
  • Azzad Asset Management sold 9,384 Pacira BioSciences shares in Q2 2024, an estimated $274K.
  • Azzad Asset Management first reported a position in Pacira BioSciences in Q3 2020 and held it in 14 quarters.
  • Azzad Asset Management's Pacira BioSciences position peaked at $332K in Q1 2021.
  • 280 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2024.

Based on Azzad Asset Management's 13F filing for Q2 2024, filed 30 Jul 2024.